This article is more than 5 years old. Information may no longer be current.
PsychoGenics, Alzheimer’s Drug Discovery Foundation partner to advance Alzheimer’s disease research
Click Here to Manage Email Alerts
PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation recently announced a new partnership that will enable Alzheimer’s Drug Discovery Foundation grantees access to validated Alzheimer’s disease animal models and experimental services from PsychoGenics.
“We are delighted to collaborate with PsychoGenics to make its expertise and services available to our Alzheimer’s research community,” Howard Fillit, MD, executive director and chief science officer of the Alzheimer’s Drug Discovery Foundation, said in a press release. “This beneficial partnership will allow our critical funding to go further. Together, we will accelerate preclinical drug discovery programs in our portfolio and move closer to our goal of developing new treatments for Alzheimer's disease.”
Under the agreement, PsychoGenics will form risk-sharing agreements with biotechnology companies funded by the Alzheimer’s Drug Discovery Foundation to offer PsychoGenics services under favorable financial terms, according to the release.
Available services include behavioral pharmacology, electrophysiology, translational electroencephalogram, microdialysis, a variety of biochemical methods, quantitative histological methods and several tauopathy animal models.
“We are extremely pleased to align with the [Alzheimer’s Drug Discovery Foundation], an organization that enables leading scientists to pursue cutting-edge research projects that might otherwise go unexplored. Programs that apply for [Alzheimer’s Drug Discovery Foundation] funding go through a very rigorous review process and those that are funded hold great promise,” Emer Leahy, PhD, president and CEO of PsychoGenics, said in the release. “Through our risk-sharing arrangement, we can help some of the most promising programs go further and fast track the development of effective therapies for the significant unmet medical needs associated with Alzheimer's disease, dementia and cognitive aging.”